• Your pet must have a diagnosis of one of the following cancers:
  • Osteosarcoma
    • Patients with a probable diagnosis of osteosarcoma can be enrolled (this can be based on imaging and patient history)
  • Hemangiosarcoma
    • For hemangiosarcoma, your pet MUST have a definitive diagnosis (this means a diagnosis based on cell aspirates/cytology or a tissue sample/biopsy)
    • Exceptions will be made for patients with right atrial masses
  • Urothelial carcinoma involving the bladder/urethra/prostate (transitional cell carcinoma of the bladder/urethra/prostate)
    
    • Patients with a BRAF positive urine test result and bladder/urethral/prostatic mass on ultrasound are eligible for this study, even without a cell or tissue sample confirming a diagnosis
  • Please note: we are NOT accepting any other patients/diagnoses for the EGFR/HER2 vaccine at this time. This vaccine CANNOT be given outside of the clinical trial for other cancer types (no exceptions).
• Your pet must have thoracic radiographs (lung x-rays) performed within 1 week of receiving the first vaccine (or at the time of the first vaccine, which can be done with VCCS). For hemangiosarcoma and urothelial carcinoma patients, an abdominal ultrasound must be completed within 1 month of receiving the first vaccine.
• Your pet must have an expected survival of >3 months. This will depend on the extent of cancer present (ie if the cancer has already spread and what treatments the patient is receiving), and what other conditions/diseases your pet has. This will be determined by our doctors on staff.

• Two required visits with VCCS: Your pet will receive a series of 2 vaccines, spaced 3-4 weeks apart. Your pet can receive a third booster vaccine 1 year from the first vaccine if you are interested.
  • NOTE: the vaccines must be given with VCCS. We are unable to ship these vaccines to a location closer to you.
• The vaccine is a very small amount of liquid injected under the skin (usually between the shoulder blades)
• The following monitoring schedule is required (and can be done with your local veterinarian or oncologist if more convenient for you):
  • Baseline bloodwork (CBC/chemistry panel) and a urinalysis at the time of the first vaccine (if not done within the past week)
  • Baseline blood draw for serum sample collection (this will be sent to Yale for monitoring an immune response; please note that no results are reported for this)
  • Blood draw for serum sample collection at the time of the second vaccine
  • Continued monitoring at the following time points (can be done with your local veterinarian or oncologist):
    • Day 45-55 (from the first vaccine) blood draw for serum sample collection to be sent directly to Yale
    • 3, 6, and 9 months (from the first vaccine) for: blood draw for serum sample collection to be sent directly to Yale, three-view thoracic radiographs with radiology report, and an abdominal ultrasound (for hemangiosarcoma and urothelial carcinoma/TCC patients only; the abdominal ultrasound is not required for osteosarcoma patients)

No – this is a partially funded trial. The patient will have access to the vaccine at no cost to the client, although all other fees (consultation/exam fees, drug administration fees, and test fees involved in monitoring) are the responsibility of the client).

• If you already have a local oncologist managing your pet’s care, then a consultation is not required. In this case, we will need your oncologist to fill out the referral form on our website. Please note that we will not schedule the first vaccine appointment until receiving all of your pet’s medical records. Referral Form
• For clients that do not have an oncologist managing their pet’s cancer care, an oncology consultation with VCCS is required. For naive patients, a full oncology consultation will be provided and additional therapies discussed if applicable. For more information, please contact us directly.